logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-17. Route of administration of primary drug as main reason for asking treatment among new and all outpatient clients in 2005 [see all tables in this series...]

Part (vi) Percentage amongst all clients with cocaine (HCl and crack) as primary drug

CountryInjectSmoke/inhaleEat/drinkSniffOthersBase (known status)Status unknown
Bulgaria0.00.00.0100.00.030
Czech Republic0.00.00.0100.00.050
Denmark10.410.43.176.00.019227
Germany32.826.11.432.86.964437445
Ireland12.15.60.082.40.03068
Greece7.637.91.553.00.0665
Spain(1)5.712.90.761.619.221713358
France14.037.30.747.01.0719251
Italy6.363.50.030.20.0101770
Cyprus6.139.40.054.50.0331
Lithuania12.50.012.575.00.080
Luxembourg47.52.50.050.00.0400
Hungary9.43.510.676.50.085
Malta17.517.50.062.52.5402
Netherlands(2)1.153.81.240.23.72954369
Slovakia25.00.00.050.025.040
Finland50.050.00.00.00.040
Sweden2.02.04.191.80.0494
United Kingdom(3)4.754.03.833.54.084422109
Total9.034.01.245.99.95128310579

Notes:

 Only countries where there are clients reported with cocaine (HCl and crack) as primary drug are shown. 

 (1) Data from Spain refer to 2004. 

 (2) Data refer to outpatient treatment centres and low-threshold agencies. 

 (3) Data refer to collection period between 01.04.2004 and 31.03.2005. 

 See also 'Table TDI-110' for cocaine CIH and crack route of administration distribution, and 'General notes for interpreting data' on the Explanatory notes and help page

Sources:

 2006 Reitox national reports - TDI - outpatient treatment centres. 

Page last updated: Monday, 12 November 2007